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Abstract
Monoclonal antibodies (mAbs) currently dominate the biopharmaceutical sector due to
their potency and efficacy against a range of disease targets. These proteinaceous
therapeutics are, however, susceptible to unfolding, mis-folding, and aggregation by
environmental perturbations. Aggregation thus poses an enormous challenge to
biopharmaceutical development, production, formulation, and storage. Hydrodynamic
forces have also been linked to aggregation, but the ability of different flow fields (e.g.,
shear and extensional flow) to trigger aggregation has remained unclear. To address
this question, we previously developed a device that allows the degree of extensional
flow to be controlled. Using this device we demonstrated that mAbs are particularly
sensitive to the force exertedas a result of this flow-field.Here, to investigate theutility
of this device to bio-process/biopharmaceutical development, we quantify the effects
of the flow field and protein concentration on the aggregation of threemAbs.We show
that the response surface of mAbs is distinct from that of bovine serum albumin (BSA)
and also that mAbs of similar sequence display diverse sensitivity to hydrodynamic
flow. Finally, we show that flow-induced aggregation of each mAb is ameliorated by
different buffers, opening up the possibility of using the device as a formulation tool.
Perturbation of the native state by extensional flow may thus allow identification of
aggregation-resistant mAb candidates, their bio-process parameters and formulation
to be optimized earlier in the drug-discovery pipeline using sub-milligram quantities of
material.
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1 | INTRODUCTION
The advent of hybridoma (Kohler & Milstein, 1975) and phage display
technologies (Winter, Griffiths, Hawkins, & Hoogenboom, 1994) has
allowed monoclonal antibodies (mAbs) to revolutionize the biotech-
nology industry (Aggarwal, 2014). Since the approval of Orthoclone
OTK3 in 1986, over 50 mAb-based biologics have been launched,
comprising half of the $140 billion biopharmaceutical market (Chiu &
Gilliland, 2016; Elgundi, Reslan, Cruz, Sifniotis, & Kayser, 2017). The
ability to generate high affinity candidates to a broad range of targets,
together with the development of multi-partite therapeutic strategies,
has rendered mAbs and their derivatives important scaffolds
(Aggarwal, 2014).
One barrier that slowsor evenhalts the process of bringingmAbs to
market is aggregation (Buss, Henderson, McFarlane, Shenton, & de
Haan, 2012) due to unfolding (partial or complete) or mis-folding
(Mahler, Friess, Grauschopf, & Kiese, 2009; Roberts, 2014). While
generally deleterious to protein function, aggregation is particularly
problematic to the biopharmaceutical industry as aggregates have been
linked to immunogenic reactions in patients (Büttel et al., 2011) and to
shortened therapeutic half-life (Dobson et al., 2016). In addition, the
presence of aggregates during development can lead to a decreased
yield and an increase in time to market, due to the need to optimize
manufacturing conditions/formulation (Cromwell, Hilario, & Jacobson,
2006; Zurdo et al., 2015). mAb-based biologics are susceptible to
aggregation throughout their lifetime, from over-expression in the cell
(Kramarczyk, Kelley, & Coffman, 2008) and downstream processing
(Skamris et al., 2016; Yu et al., 2016) to the final fill-finish step at high
concentration (Cromwell et al., 2006; Rathore & Rajan, 2008). In
contrast to the effects of temperature and pH (reviewed in Roberts,
2014), the effects of biopharmaceutical manufacture and transport
stresses, such as air-water interfaces (Beeet al., 2012;Maa&Hsu, 1997)
and hydrodynamic forces (Biddlecombe et al., 2007; Brückl, Schröder,
Scheler, Hahn, & Sonderegger, 2016), are relatively under-studied
(Bekard, Asimakis, Bertolini, & Dunstan, 2011; Thomas & Geer, 2011).
The ability to assess aggregation propensity is essential for any
biopharmaceutical, includingmAb-based products, to progress success-
fully from molecule to market (Jain et al., 2017; Tiller & Tessier, 2015;
vanderKant et al., 2017). In silico analyses, such as TANGO (Fernandez-
Escamilla, Rousseau, Schymkowitz, & Serrano, 2004), Zyggregator
(Tartaglia & Vendruscolo, 2008), Waltz (Oliveberg, 2010), Aggrescan
(Conchillo-Solé et al., 2007), and PASTA (Trovato, Seno, & Tosatto,
2007) can be used to predict the presence of aggregation-prone regions
(APRs) within proteins using protein primary sequence information
alone. In addition, CamSol (Sormanni, Aprile, & Vendruscolo, 2015) and
SAP can be used to predict aggregation-prone (poorly soluble) surface-
exposed regions (Chennamsetty, Voynov, Kayser, Helk, & Trout, 2009;
Trainor, Broom, & Meiering, 2017) while Solubis (Van Durme et al.,
2016) integrates thermodynamic data, allowing identification of buried
APRs that may be transiently exposed (van der Kant et al., 2017). A
caveat of these latter in silicomethods is the necessity of high resolution
structural data for the molecule under study. These developing in silico
approaches complement established accelerated stress studies that are
performed in vitro to predict the shelf-life and stability of biologics (Jain
et al., 2017; Yang et al., 2013). Various methods are employed to
generate such data including heating (Chenget al., 2012;Hamrang et al.,
2015), stirring (Luo et al., 2011; Sediq, Van Duijvenvoorde, Jiskoot, &
Nejadnik, 2016), shaking (Kiese, Papppenberger, Friess, &Mahler, 2008;
Rudiuk, Cohen-Tannoudji, Huille, & Tribet, 2012), and simulation of
transportation (Fleischman, Chung, Paul, & Lewus, 2017). The extent of
aggregation, however, can be heavily dependent on the type of
accelerated stress employed (Fleischman et al., 2017; Joubert, Luo,
Nashed-Samuel, Wypych, & Narhi, 2011; Tamizi & Jouyban, 2016).
Differences in accelerated and innate aggregation propensities
(Goldberg et al., 2017) may arise because the acceleration method
increases the relative flux through certain pathways which are distinct
to those traversed during production or upon storage (Chakroun,
Hilton, Ahmad, Platt, & Dalby, 2016; Luo et al., 2011; Phillips et al.,
2017; van der Kant et al., 2017). There is thus a need to develop stress
tests that more closely replicate the conformational ensemble
generated during processing and transport. In light of this, we and
others have shown that hydrodynamic extensional flow fields
encountered during the nano-filtration, pumping, and fill-finish steps
of bio-processing can trigger protein aggregation (Charm & Wong,
1981; Dobson et al., 2017; Simon, Krause, Weber, & Peukert, 2011;
Wolfrum, Weichsel, Siedler, Weber, & Peukert, 2017). Using a
reciprocating extensional and shear flow device (EFD) (Figure 1a),
we showed that extensional flow fields can induce the conformational
unfolding/remodeling of bovine serum albumin (BSA, Figure 1b),
leading to aggregation that was characterized and quantified by an
array of biophysical techniques including DLS, NTA, and TEM (Dobson
et al., 2017). By subjecting five other globular proteins that varied in
sequence, size, and structure to such flow stresses, we demonstrated
that the aggregation propensity of proteins differed based on their
fold, sequence, and the fluid fields to which they are subjected
(Dobson et al., 2017). For mAb-based biotherapeutic scaffolds we
observed a wide-range of sensitivity to flow-induced aggregation
under identical conditions (strain rate, pass number, protein concen-
tration and buffer), dependent on the protein sequence (Dobson et al.,
2017). Accordingly, the aggregation-prone antibody (MED-
I1912_WFL, WFL herein, Figure 1b) was found to be most sensitive
to extensional flow, while its rationally engineered aggregation-
resistant derivative (MEDI1912_STT, STT herein, Figure 1b (Dobson
et al., 2016) showed markedly decreased aggregation (∼85 and ∼5%
aggregation, respectively). An unrelated mAb, mAb1, showed inter-
mediate behavior (Dobson et al., 2017). For BSA, the extent of
aggregation is dependent on the magnitude of the strain rate, the total
exposure time to the extensional flow event (controlled by both the
number of passes and plunger velocity) and the protein concentration,
producing a complex aggregation landscape. These observations
suggest that the flow-induced aggregation of mAbs may proceed via a
common mechanism, resulting in the formation of insoluble, amor-
phous aggregates (Figure 1c). Here, using the EFD and a protein
pelleting assay, we havemapped in detail the aggregation landscape of
WFL, STT, and mAb1 after exposure to defined fluid fields, exposure
times, and protein concentrations. These experiments reveal distinct
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behavior under flow for these structurally similar proteins. Addition-
ally, we show that the same protein can exhibit diverse behavior under
flow, dependent on the buffer used. Quantifying extensional flow-
induced aggregation of mAbs may thus allow the rational selection of
more robust biopharmaceuticals and the identification of buffer and
manufacturing conditions which minimize aggregation.
2 | MATERIALS AND METHODS
2.1 | Protein sample preparation
The proteins used in the study (WFL, STT, and mAb1) were
provided by MedImmune Ltd, Cambridge UK, as described
previously (Dobson et al., 2016, 2017). Buffer reagents were
obtained from Sigma–Aldrich (Gillingham, UK), except sodium
phosphate dibasic (BDH Lab Supplies, Bristol, UK) and L-arginine
(Acros Organics, Geel, Belgium). In all experiments, antibodies
were dialyzed into the appropriate 0.22 μm-filtered and de-gassed
buffer and subsequently used in extensional flow experiments.
Bovine Serum Albumin (BSA) was prepared as described previ-
ously (Dobson et al., 2017). Except for the buffer screen, all mAb
experiments were performed in 150 mM ammonium acetate
buffer, pH 6.0. For experiments involving BSA, 25 mM ammonium
acetate buffer pH 5.1 was used.
2.2 | Extensional flow device (EFD) and stress
experiments
Full details of the extensional flow device including its validation
using computational fluid dynamics (CFD) are described elsewhere
FIGURE 1 Extensional flow-induced protein aggregation. (a) Schematic of the extensional flow device (EFD). Protein solution is driven from
the syringe (left) though the capillary via a stepper motor. The fluid velocity is slow and laminar in the syringe. The abrupt contraction in the
flow, where the capillary connects the syringes, causes a rapid increase in fluid velocity, generating an extensional flow. A high shear flow is
then established along the length of the capillary. Computational fluid dynamics profiles (Dobson et al., 2017) of velocity (top) and strain rate
(bottom) highlight the extensional flow field. The protein solution then enters the other syringe, ready to be shuttled back on the next pass.
(b) Structures of BSA (PDB ID: 3V03) (Majorek et al., 2012), WFL and STT. The surface-view scFv models of WFL and STT were built from
the structure of their parent, MEDI_578 (PDB ID: 5jz7) (Dobson et al., 2016). The surface for each protein is color-coded according to the
CamSol structurally corrected solubility profiles of WFL and STT to show regions of poor solubility (red) and enhanced solubility (blue)
(Supplementary Methods). (c) Proposed mechanism of flow-induced mAb aggregation. (i) The native protein (blue) is perturbed into an
aggregation-prone state (red), the relative level of which is dependent on the fluid field and the protein studied. (ii) This can either re-fold to
the native state or proceed along the aggregation pathway (iii) to form irreversible, insoluble aggregates (iv). The apparent rate constants (kf
and kr) represent the rate of formation/refolding of the aggregation-prone state, while kf
’ and kr
’ represent the concentration-dependent rate
of oligomer formation and the unimolecular off-rate for oligomer dissociation, respectively. These rate constants remains to be determined
1218 | WILLIS ET AL.
(Dobson et al., 2017). Briefly, the EFD consists of two modified
Hamilton gas-tight syringes (inner diameter = 4.6 mm) connected by
a 0.3 mm inner-diameter borosilicate glass capillary. The capillary
length was 75mm in all experiments except shear-length variation
experiments, where a ceramic cutter was used to shorten capillaries
to 50 mm (2/3 length) or 37.5 mm (1/2 length) followed by flame-
finishing. All protein solutions were 0.22 μm-filtered prior to loading
into the device, and any air-bubbles ejected prior to assembling the
EFD. The protein solution was shuttled between the syringes at the
desired plunger velocity (determining the strain rate and the shear
rate) for a given number of passes (determining exposure time); see
Supplementary Table S1 for plunger velocities and concomitant
center-line strain and shear rates. The plungers were driven by a
stepper motor controlled by an Arduino microcontroller. After
subjecting the protein to the desired number of passes, the EFD was
dissembled and the protein solution removed for quantification of
aggregation (insoluble protein pelleting assay, below). All experi-
ments were performed at a concentration of 0.5 mg ml−1 for mAbs
and 5mg ml−1 for BSA unless stated otherwise. As a control, a
sample was incubated under ambient conditions (quiescent)
alongside the stressed sample for the duration of the experiment
and subsequently subjected to the same analysis.
The buffer screen was carried out in five buffers: 10mM L-
histidine pH 6.0; 10mM sodium acetate pH 6.0; 10mM sodium
succinate pH 6.0; 10mM sodium phosphate pH 7.2; and 125mM L-
arginine + 20mM sodium succinate pH 6.0.
2.3 | Insoluble protein pelleting assay
The insoluble protein formed after stress in the flow device was
quantified using an insoluble protein assay (Dobson et al., 2017).
Briefly, 2 × 200 μl of the protein sample under test (stressed or
quiescent) was centrifuged at 30,000 rpm in a Beckmann Coulter
Optima TLX ultracentrifuge, equipped with a TLA100 rotor for 30min.
A total of 150 μl of supernatant was then removed from each tube. A
total of 200 μl 6M guanidine hydrochloride buffer, pH 6.0 was added
to 50 μl of this supernatant (giving [S] after quantification, Equation 1)
and to the ∼50 μl solution (including the insoluble fraction) that
remained in the ultracentrifuge tube (giving [P] after quantification,
Equation 1) and incubated at 4°C overnight. The concentration of
solubilized protein was quantified using UV spectroscopy at 280 nm
using extinction coefficients of 43824, 207360, 239440, and
228440M−1 cm−1 for BSA, mAb1, WFL, and STT, respectively. The
% pelleted protein was calculated using equation 1:
% protein in pellet ¼ P½   ½Sð Þ
protein½ 0
 
 !
 100 ð1Þ
where [P] is the concentration of protein in the pellet fraction, [S] is the
concentration of protein in the supernatant fraction and [protein]0 is
the initial protein concentration.
Data were analyzed and plotted using Microsoft Excel 2015 and
Origin 2017, respectively.
2.4 | Supplementary online material
Supplementary Methods describe 3D aggregation landscape plotting,
intrinsic solubility calculations using CamSol and a table that lists the
center-line strain rate and capillarywall shear rate associatedwith each
plunger velocity. Supplementary Results show the effect of low strain
rates in the aggregation of WFL and STT.
3 | RESULTS
3.1 | Mapping the aggregation behavior of WFL and
STT
We showed previously that the extent of flow-induced aggregation of
different proteins is sensitive to the strain rate and exposure time (and
protein concentration) when modulated independently. For example, for
BSA, a center-line strain rate of at least 14,634 s−1 (a plunger speed of
10mms−1)was requiredbeforesignificantquantitiesofaggregatedprotein
could be detected after 100 passes (data along green line, Figure 2a and
Dobson et al., 2017). This suggests that a force threshold, applied from the
flow onto the protein in the extensional flow field, has to be overcome to
induce local unfolding and subsequent aggregation of the protein.
However, as partial unfolding is assumingly a stochastic process, the
extent of aggregation was also found to be pass number dependent (red
line, Figure 2a). To investigate the co-dependence of these variables, BSA,
WFL, and STT were stressed for different numbers of passes at different
plunger velocities (Methods and SupplementaryMethods). The amount of
insoluble protein formedunder each flowconditionwas quantified and the
data thenplottedasa three-dimensional responsesurface (Figure2a–cand
SupplementaryMethods). As observedpreviously, it is clear from the three
surfaces that each protein displays distinct sensitivity to flow-induced
aggregation, with BSA most resistant and WFL most sensitive. BSA, the
aggregation of which (at a plunger velocity of 8mms−1) was characterized
in detail in our previous study (Dobson et al., 2017), has a relatively flat
aggregation landscape (Figure 2a); below 10mms−1, little aggregation is
induced, irrespective of pass number. Above this plunger velocity,
aggregation becomes dependent on both the plunger velocity and pass
number, so that after 200 passes at 16mms−1, ∼30% of BSA is rendered
pelletable STT displays a similar profile (Figure 2b) but with a greater
aggregation propensity. After 50 passes, STT shows little aggregation over
the investigated rangeofplungervelocities (strain rates), and the increase in
aggregation with the number of passes is small at slow plunger velocities.
The aggregation landscape of STT is relatively flat and low in magnitude in
regionswhere thestrain rateand/orpassnumber is small.As thenumberof
passes andplunger velocity increases, the rise in aggregation is significantly
greater than for BSA (e.g., 95% of STT is insoluble after 200 passes at a
plunger velocity of 16mms−1). This concurs with the hypothesis that
traversing the extensional flow region of the device promotes the
population of transient aggregation-prone, partially unfolded species that
then interact, triggering aggregation. The relative population of these
speciesover thetimecourseof theexperimentmaybe increasedbygreater
energy input (faster flows) or by increasing thenumber of opportunities for
partial unfolding to occur (increased pass number).
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In contrast to these data, the response surface ofWFL shows only
a simplemonotonic profile (Figure 2c), where aggregation is dependent
solely on pass number above 2mm s−1. For example, at 8 mm s−1
aggregation increases from ∼35 to 100% upon increasing from 20 to
100 passes (red line, Figure 2c). Despite the velocity independence,
hydrodynamic flow is still necessary to induce aggregation, as minimal
aggregation is observed under quiescent conditions. Above the
2mm s−1 threshold, the number of passes through the device dictates
the amount of aggregate observed (∼90–100% after 100 passes). For
WFL, these data suggest that (i) the aggregation-prone patches of the
protein are exposed to the solvent upon experiencing a relatively small
strain rate (6,031 s−1) or that (ii) the protein maintains its aggregation-
prone state after traversing the extensional flow region or that (iii) the
affinity/on-rate for WFL oligomerization is higher relative to STT.
For bothWFL and STT, not all strain rates bring about aggregation.
When WFL was stressed at 0.5 mm s−1 for 20 passes, minimal
aggregation was observed, whereas when STT was stressed for 50
passes at 0.5 mm s−1 no aggregation was observed (Figure S1). Flow-
induced protein aggregation thus appears to be a complex function of
the force that the protein is exposed to and the number of times the
protein experiences exposure to this force, convoluted with the on-
and off-rates of aggregation. This multi-factorial dependence results in
distinct aggregation landscapes for even very closely related proteins.
3.2 | STT and WFL exhibit different concentration
dependencies of aggregation
The data above suggest a mechanism whereby aggregation is driven by
inter-molecular collisions between activated species and/or with ground-
state proteins. Next, we sought to examine whether increased protein
concentration resulted in increasedaggregate formationunder equivalent
flow conditions, as expected from such a model. Accordingly, WFL and
STT were stressed for 100 passes at a concentration of 0.5, 1, 2, and
5mgml−1 at a plunger velocity of 8mm s−1 and the extent of aggregate
formation was quantified. Once more, STT and WFL showed diverse
behavior (Figure 3). For STT, protein concentration strongly affected the
aggregation probability, increasing from 15 to 88% at 0.5 and 2mgml−1,
respectively. After this point, no further increase in the percent of
aggregationwasobserved, suggesting thatat aconcentrationof2mgml−1
or higher, the aggregation reaction had reached its end point by 100
passes.WFL, by contrast, showedalmost complete aggregation (94%) at a
concentration as low as 0.5mgml−1. WFL and STT only differ by three
residues ineachVHdomain (two inCDR1andone inCDR2) (Dobsonet al.,
2016). The intrinsic solubility scores (i.e., based on primary sequence
alone) of CDRs 1 and 2, calculated using CamSol, yields values of 0.005
and 0.302 for WFL and 1.347 and 0.505 for STT, respectively
(Supplementary Methods). The CDR1 of STT is therefore predicted to
be markedly more soluble (greater positive CamSol score) than the same
region inWFL (Sormanni et al., 2015). These data suggest either that flow
perturbs thestructureof theseCDRs,exposingaggregation-proneregions
to the solvent to different extents for WFL and STT, and/or that the
exposed APRs have different affinities. Previous cross-linking studies
under quiescent conditions have shown that WFL homodimer formation
occurs via VH-VH interactions, with the binding interface comprising
residues30,31 (CDR1), and56 (CDR2) (Dobsonetal., 2016).Whether the
same interface is formed under extensional flow remains to be seen.
3.3 | Aggregation-prone mAbs are sensitive to high
shear
The EFD generates a well-defined region of extensional flow at the point
of contraction, followed by shear flow along the length of capillary
(Figure 1a) (Dobson et al., 2017). Shear flow within the capillary
(characterized by the shear rate) could thus play a role in aggregation,
FIGURE 2 Aggregation landscapes of (a) BSA, (b) STT, and (c) WFL. The 3D surface plots show the percentage of insoluble protein formed
after stress in the flow device for the given number of passes at a range of strain rates (3,184–23,421 s−1; see Supplementary Table S1). (a)
BSA was stressed for 200 passes at a concentration of 5mgml−1 in 25mM ammonium acetate, pH 5.1. These data were plotted alongside
the data obtained for 100 passes from (Dobson et al., 2017). Total number of data points = 18 (including quiescent samples). (b and c) The
two antibodies (STT and WFL, respectively) were stressed at a concentration of 0.5 mgml−1 in 150mM ammonium acetate buffer, pH 6.0.
Total number of data points = 45 per surface (including border from quiescent samples). Red lines indicate the response to increasing passes
at a plunger velocity of 8 mm s−1. Green lines indicate the response to increasing strain rate and 100 passes through the device. All data
shown are the average of two independent experiments
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despite a much smaller rate of energy transfer per unit time (28 (E/kBT.t)
s−1 vs 150,000 (E/kBT.t) s
−1 for the shear and extension regions
respectively at a plunger velocity of 8mm s−1 (Dobson et al., 2017)).
For BSA, this possibility was obviated as aggregation was found to be
independent of capillary length, using flow conditions underwhich BSA is
most susceptible to aggregation (plunger velocity of 16mm s−1) (Dobson
et al., 2017). The data for WFL and STT above, however, show that the
aggregation landscapes for mAbs differ from that of stable, globular
proteins such as BSA. To determine the effect of shear flow on mAb
aggregation, WFL and STT were subjected to 20 and 100 passes
(respectively, to generate a similar aggregate yield) at a plunger velocity of
8mm s−1, using capillary lengths of 37.5, 50, and 75mm (Methods). The
extent of aggregation was then quantified using the pelleting assay.
Figure 4 shows that the aggregation of STT is independent of capillary
length, but that WFL aggregation decreases from 37% to 15% upon
halving the capillary length, indicating that shear flow contributes to the
aggregation of this protein. Further work is required to identify the
underlying mechanism behind this observation. For example, this effect
may arise because the key aggregation-prone region of WFL may be
exposedata lowerstrain rate thresholdorbecause thepresenceofashear
region may slow the relaxation time of the activated species. Irrespective
of the mechanism, the results show that these highly homologous mAbs
display diverse behavior under flow.
3.4 | mAb1 exhibits traits of both WFL and STT in
response to flow
While comparing the biophysical properties of STT and WFL under
quiescent and flow conditions is an extremely powerful method
to delineate the mechanism and determinants of flow-induced
aggregation, these proteins may represent extremes of the mAb
scaffolds usually encountered during bio-processing. We thus
complemented the above data by examining the (plunger velocity
(2–16 mms−1), pass number (0–100) and shear exposure time (37.5,
50, and 75 mm) dependencies of mAb1, an unrelated IgG1 that has
∼72% sequence identity to WFL and STT (Dobson et al., 2016,
2017). The data in Figure 5a show that, similarly to WFL and STT,
the extent of mAb1 aggregation is directly dependent on pass
number and that mAb1 displays intermediate sensitivity to pass
number (rank order: WFL>mAb1>STT). Like STT (Figure 4), the
aggregation of mAb1 is independent of the length of the shear
region (31.1 ± 1% and 29.6 ± 2% for full- and half-length capillaries,
respectively) (Figure 5b). mAb1 also displays a STT-like response in
aggregation level to an increase in plunger velocity, with low levels
of aggregation observed at 2 mm s−1 and increased levels of
aggregate with increasing strain rate (Figure 5c). Comparison of
these three IgG1s reveal that their primary sequence modulates
flow-induced aggregation, producing complex and distinct land-
scapes dependent on the sequence and flow conditions used.
3.5 | Using the EFD as a buffer screening tool
Thebuffer composition (ionic strength, buffering salt, and pH) is known
to affect the processability and formulated stability of biopharma-
ceuticals (Dobson et al., 2016; Goldberg et al., 2017; Wang, 2015). To
FIGURE 3 Effect of protein concentration on WFL and STT
aggregation under flow stress. WFL and STT were stressed for 100
passes at a plunger velocity of 8mm s−1 over a range of concentrations
(0.5, 1, 2, and 5mgml−1) in 150mM ammonium acetate pH 6.0, then
analyzed with the pelleting assay. Points represent the relative amount
of insoluble WFL (black squares) and STT (gray squares). Error bars
indicate the error from two independent experiments
FIGURE 4 Shear-length dependence on WFL and STT
aggregation. Decreasing the length of the borosilicate glass capillary
decreases the length of time proteins are exposed to high shear
downstream of the extension region. WFL was stressed for 20
passes at a plunger velocity of 8 mm s−1, while STT was stressed for
100 passes at the same plunger velocity. The capillary wall shear
rate in the capillary = 50,375 s−1. Bars show percentage insoluble
WFL (black bars) and STT (gray bars) formed following stress using
capillaries of differing length. Capillary length was either 75mm
(full-length), 50mm (2/3), or 37.5mm (half-length). The quiescent
samples were not exposed to flow stress. Both proteins were
stressed at a concentration of 0.5 mgml−1 in 150mM ammonium
acetate buffer, pH 6.0. Error bars indicate the error from two
independent experiments
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assess the effect of buffer composition on stability under flow, STT,
WFL, andmAb1were dialyzed into four buffers in which the quiescent
stability of STT and WFL is known, as well as arginine + succinate
buffer (Methods) (Dobson et al., 2016). Each mAb (0.5 mgml−1) was
then stressed for 100 passes at 8 mm s−1 and the resulting aggregation
quantified. The results show that the ability of each buffer tomodulate
aggregation is dependent on the mAb sequence (Figure 6). For
example, the high flow sensitivity of WFL aggregation was largely
maintained in all buffers, with arginine + succinate a noteworthy
exception (aggregation decreased from ∼86% in histidine, acetate,
succinate, and phosphate buffers to 20% in arginine + succinate
buffer). Interestingly, both STT and mAb1 displayed buffer-dependent
levels of flow-induced aggregation. These effects were mAb-
dependent, with STT showing a greater extent of aggregation in
histidine compared with phosphate and vice-versa for mAb1. Given
arginine's widespread use as a stabilizing excipient (Baynes, Wang, &
Trout, 2005; Kim, Hada, Thapa, & Jeong, 2016), it is also of note that all
mAbs exhibit greatly suppressed aggregation in arginine + succinate
buffer. Extensional flow-induced mAb aggregation is thus sensitive to
both the buffer used and the mAb sequence. Previous work to identify
the buffer which afforded STT the greatest stability used dynamic light
scattering. This required higher protein concentrations (4 mgml−1)
(Dobson et al., 2016) and showed limited ability to differentiate
between buffers. The results presented here suggest that extensional
flow stress tests could be used to screen the stability of mAbs in
different buffer environments and hence to optimize conditions in the
pipeline for biologics production, using as little as 0.25mg of protein
per experiment.
4 | DISCUSSION
Examining the effect of both the magnitude and duration of defined
hydrodynamic stresses on protein solutions has been carried out on
several globular proteins (Dobson et al., 2017; Simon et al., 2011).
Performing such experiments on proteins of more complex topology
and inherent commercial value, such as mAbs, is useful to both the
biotechnology industry and the wider scientific community. We show
here that the aggregation response of WFL and STT to flow are
distinct, despite these mAbs differing by only three residues per VH
domain. WFL formed large amounts of insoluble protein under flow,
even when exposed to low strain rates for as few as 20 passes. By
contrast, the STT aggregation landscape shows a much larger region
where few aggregates form. Such an analysis could inform
FIGURE 5 Aggregation behavior of mAb1 under different flow conditions. (a) Plot of percentage insoluble mAb1 formed as a result of a
defined number of passes through the flow device at a plunger velocity of 8 mm s−1 (white squares). Data for WFL (▪) and STT (▪) (data taken
from red lines in Figures 2c and b, respectively) are shown for comparison. Linear trend lines to guide the eye are shown for WFL (solid black
line), mAb1 (dashed line), and STT (dotted line), respectively. (b) Shear length variation on mAb1 stressed for 50 passes at a plunger velocity
of 8 mm s−1 with capillaries of varying length. Full-length = 75mm, 2/3 = 50mm, and half-length = 37.5mm. (c) mAb1 aggregation after 100
passes through the flow device at different plunger velocities (2–16mm s−1). mAb1 was stressed in 150mM ammonium acetate, pH 6.0 at a
concentration of 0.5 mgml−1 in all experiments. Error bars indicate the error from two independent experiments
FIGURE 6 Using the EFD to screen optimal buffers for WFL,
STT, and mAb1. WFL (black bars), STT (gray bars), and mAb1 (white
bars) were dialyzed into 10mM L-histidine pH 6.0, 10mM sodium
acetate pH 6.0, 10mM sodium succinate pH 6.0, 10mM sodium
phosphate pH 7.2, and 125mM L-arginine + 20mM sodium
succinate pH 6.0 and stressed for 100 passes in the device at a
plunger velocity of 8 mm s−1. Error bars indicate the error from two
independent experiments
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manufacturing practice through relating the strain rates and exposure
times experienced in the EFD to plant equipment (e.g., the multiple
passes experienced in a tangential flow filtration device (Rosenberg,
Hepbildikler, Kuhne, & Winter, 2009)). To do this, studies of plant
equipment need to report strain rates due to extensional flow
alongside the more commonly reported shear rates (Bee et al., 2009;
Charm & Wong, 1981).
It has been suggested that shear flow does not cause damage to
the tertiary structure of proteins (Bee et al., 2009), and/or that the
shear rates required to do so may be hard to achieve experimentally
(Jaspe & Hagen, 2006). We show here, however, that reducing the
amount of time the protein is exposed to high shear (by decreasing the
length of the capillary),WFL aggregation is diminished, indicating a role
for shear in the process (note: at a plunger velocity of 8 mm s−1,
proteins spend ∼18 µs in the extension region, 40ms in the capillary,
and ∼5 s in the syringes (Dobson et al., 2017)). Whether shear alone or
an initial extensional flow event prior to shear is required to induce
WFL aggregation remains to be seen. The latter scenario could cause a
localized unfolding of a protein molecule (e.g., as seen for von
Willebrand factor (Lippok et al., 2016) and for BSA in our previous
study (Dobson et al., 2017), which may then be susceptible to
“tumbling” events under shear flow in the capillary (Smith, Babcock, &
Chu, 1999) and rapid self-association in a concentration and time-
dependent manner.
The mAb1 antibody exhibited “intermediate” behavior when
subjected to the same experiments as WFL and STT. mAb1 showed a
linear pass number dependence (similar to WFL and STT) but a strain-
sensitivity and shear-insensitivity akin to BSA and STT (Figures 2a and
2b). Taken together, our experiments point toward a common
mechanism of mAb aggregation induced by the flow fields present
in our device (Figure 1c) centered on the formation of activated,
aggregation-prone species that readily self-associate, forming soluble,
and then insoluble aggregates (Dobson et al., 2017; Roberts, 2007;
Wang, Nema, & Teagarden, 2010). The flux through the pathway is
governed by the ability of extensional flow to activate each nativemAb
into a perturbed structural state (van der Kant et al., 2017), the affinity
of the exposed APR, the rate of relaxation from the activated species
(which may itself be modulated by force [Bustamante, Chemla, Forde,
& Izhaky, 2004]) and the productive collisional frequency. Conse-
quently, mechanically robust proteins such as BSA (seventeen intra-
molecular disulfide cross-links in the native state) or, like STT, those
with reduced aggregation propensity, require the application of high
strain rates and/or pass number to induce appreciable aggregation.
The aggregation behavior of mAbs under hydrodynamic stress is
clearly affected by a variety of parameters. The defined nature of the
flow environment in the EFD can allow the effects of protein sequence
and concentration, surface chemistry (Biddlecombe et al., 2007), strain
rate, shear rate and the total exposure time on the observed
aggregation to be determined in the absence of other confounding
factors such as air-water interfaces or the action of stirring (Fleischman
et al., 2017; Joubert et al., 2011; Kiese et al., 2008; Tamizi & Jouyban,
2016; Zhao & Cieplak, 2017). Furthermore, by subjecting mAbs to
hydrodynamic stress in different buffer conditions, we have
highlighted that the choice of excipient can be another crucial factor
in influencing the extent of aggregation, opening up the possibility of
using the EFD as a formulation tool.
In summary, by mapping the response of three mAbs to defined
hydrodynamic flows, we have demonstrated that the aggregation of
these proteins can beminimized by changing processes (e.g., operating
under low strain conditions), changing sequence (WFL vs. STT), or by
changing buffer conditions.
5 | CONCLUSION
There is an unmet need to predict the aggregation propensity of
proteins of pharmaceutical interest, at an early stage in the
development pipeline, in order to maximize their chances of success
of transitioning from the bench to the market (Jain et al., 2017).
Various accelerated stress methodologies, such as stirring, heating,
and shaking, are employed to make such assessments (Tamizi &
Jouyban, 2016). Nonetheless, ranking the probability of failure
during bioprocessing remains a significant challenge. Here, we use a
well-characterized extensional and shear flow device to subject
three mAbs to defined fluid fields (strain rate, shear rate, and
exposure time). Quantifying the resultant aggregation, allows
estimation of the likelihood of biopharmaceutical aggregation under
flow and the identification of buffers that minimize the effects of
flow. This method will be a useful addition to the repertoire of tools
available to the biopharmaceutical industry to distinguish “manufac-
turable” proteins from poorer candidates, requiring only small
quantities of protein and thus allowing assessment early in the
development pipeline.
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